CDK4/6 inhibitors increase the expression of PD-L1 (programmed cell death ligand 1), thus inducing the inflammatory microenvironment and improving tumor immunogenicity (Minton, 2017; Schaer et al., 2018). Here, CDK4 is linked to neoplasm.